Women's Health Technology Market Size, Share and Global Trend By Technology Type (Surgical, Diagnostic, Contraceptive, Labor & Delivery, Critical Care), Indication (Cancer, Infertility, Menstruation, Pregnancy, Post-menopausal Syndrome, Pelvic Disorders, Infectious Diseases), End Users (Hospitals, Obstetrics & Gynaecology Clinics, Diagnostics Laboratory, Ambulatory Surgery Centers (ASC)) and Geography Forecast, 2024-2032

With women population of the world as the target customer, having to spur funding and a positive regulatory environment, women’s health technology is emerging as the next global disruptor in the healthcare market. Women’s healthcare is often incapacitated as a niche market; however, the trend is changing and this can be attributed to the rise in women’s healthcare. With the rise in digitalization, women’s health and digital health have started overlapping and is set to increase day-by-day. This market refers to diagnostics, software’s, products, and services that use technology to improve women’s health. They help motivate patients to access and use applications to manage women health issues at a more precise and personalized level than ever before.

Clinical diagnostic companies, Bio-pharmaceutical companies, and medical device companies have started to grab this market opportunity by creating various platforms for the betterment of women healthcare. With the rise in women health issues, right from menstrual health to post-pregnancy health, the market has a leveraging opportunity during the forecast period attributed to strong growth in the coming years. 

To gain extensive insights into the market, Request for Customization

Concerns raising women’s health issues such as post-menopausal syndrome, pregnancy issues, infertility, etc. are driving companies and start-ups towards introducing new products based on innovative techniques for women’s health. Increasing investment and innovative developments by the major players specifically in women’s health segment, is propelling the global market of women’s health technology.

However, lack of awareness among the general female population in emerging countries towards availability of products for women’s health, combined with the lower spending power of women in these countries is factors restraining the adoption and subsequent growth of the market. 

Key Players Covered:

Some of the key players in the global women’s health technology are Chiaro Technology Ltd and Elvie, NaturalCycles Nordic AB, Ava Science Inc., UE LifeSciences Inc., Aspect Imaging, Celmatix Inc., Rho Ventures, Evofem Biosciences, Inc., and Others.

SEGMENTATION

Among the indication segment of the global women’s health technology market, cancer, menstruation, and pregnancy segments are the major contributors to the global share of the women’s health technology market.

Key Insights

• Prevalence of Key Indications, 2018, Key Countries/ Region


• Pricing analysis


• Mergers and acquisitions

Regional Analysis:

Geographically the global women’s health technology market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the market share owing to high investments by the prominent players in the development of innovative solutions and devices for women’s health. Also, increasing incidence of breast cancer, pelvic or ureteral cancer, post-menopausal syndromes, and other diseases are driving the growth of the market in North America. The market in the Asia Pacific is projected to register comparatively higher CAGR during the forecast period owing to increasing awareness about women’s health technologies, an increase in pregnancy rates, and other health issues.

Key Industry Developments

• In April 2019, Chiaro Technology Ltd and Elvie launches the world’s first silent wearable breast pump which is hassle free, and technologically smart.


• In August 2018, NaturalCycles Nordic AB got U.S FDA approval for the first and the only contraceptive app NATURAL CYCLES, that comes with a basal thermometer and a mobile app that prevents pregnancy.


• In August 2018, UE LifeSciences Inc., received U.S.FDA approval for its iBreastExam which is a portable, hand-held device that enables medical professionals to identify breast cancer within few minutes without any pain and radiation exposure.


• In July 2017, Aspect Imaging, received U.S. FDA approval for its EMBRACE Neonatal MRI System designed specifically for neonatal brain and head imaging in neonatal intensive care units (NICU). This system does not require a radiofrequency shielded room and can be kept directly in the NICU environment.